The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said promising data suggest that the new drug "carfilzomib" could become an important new option for patients whose myeloma stops responding to other therapies. Carfilzomib, from Onyx Pharmaceuticals, is a next-generation proteasome inhibitor that disrupts the life cycle of a cancer cell, and carfilzomib has shown favorable tolerability. Based on this Phase II clinical trial, Onyx could seek accelerated drug approval from the FDA by the end of 2010.
